Market Research Logo

Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017 - 2030

Cancer is an extremely complex disease and medical science is still struggling to figure out the reasons and factors that influence the disease origin, propagation, spread (metastasis) and relapse. In 2017, a total of 1.7 million new cancer cases are estimated to be diagnosed in the US alone; during the same time period, close to 0.6 million patients are estimated to die due to cancer. The high cancer mortality rate is primarily due to delay in detection of the disease. Therefore, in addition to satisfying the unmet market need for advanced and efficient treatment interventions, early cancer diagnosis and screening form an important component of disease prevention and cure. Early diagnosis increases the survival rate that is unlikely to happen if the disease is identified at an advanced stage.

Invasive cancer diagnostic methods such as tissue biopsies have been the gold standard to determine the clinico-pathological characteristics of cancer tissues for many years. The procedure is not only cost-intensive but is also a traumatic experience for the patients. Additionally, endoscopies such as colonoscopy, gastroscopy and laparoscopy are also employed for cancer diagnosis. However, biopsies and endoscopies only offer insights of the disease state at a single point of time. They are unable to measure the disease progression or monitor the effects of the administered therapy over the treatment period. Therefore, the current cancer diagnostics market faces a pressing need for more accurate non-invasive methods of diagnosis to ensure better patient care.

There are several advanced approaches that are not only non-invasive / minimally invasive but also outweigh the limitations posed by invasive diagnostic procedures. Liquid biopsy has emerged as a promising non-invasive cancer diagnostic tool that analyzes biofluids (blood, urine or plasma) to detect rare cells and biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs) or exosomes. Moreover, liquid biopsies are capable of not only analyzing the tumor state at the time of sample extraction but can also monitor and track changes in tumor genetics over the course of treatment. In addition to liquid biopsy, the market is gradually witnessing the emergence of several other non-invasive diagnostic technologies that exploit skin lesions, bronchial fluid and exhaled breath as samples to trace signatures of cancer. These tests use gene expression profiles, biomarker analysis, volatile organic compound detection and other advanced techniques of molecular genetics to identify a particular cancer indication.

These non-invasive diagnostic techniques, backed by patient success stories, awareness and the availability of successful clinical validation data for several cancer indications, hold a significant promise and are anticipated to replace the existing invasive diagnostic tools in the coming few years. In fact, social media platforms, such as Twitter, have witnessed an increasing volume of tweets over the years. Between 2010 and 2016, we were able to identify over 7,000 tweets; this clearly indicates an upsurge in the popularity of these non-invasive tests in the given time period. With liquid biopsy on the forefront, the overall non-invasive cancer diagnostics market is likely to receive a significant boost in the near future.

SCOPE OF THE REPORT
The ‘Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030’ report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. The market is characterized by the presence of several companies that have proprietary technologies / platforms for either isolation / enrichment / enumeration of CTCs or for molecular characterization / sequencing of the genetic material extracted from the CTCs / exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, and patient and recurrence monitoring of different cancer indications. Such kits are likely to transform the cancer diagnostics market with many commercial success stories in the near future.

The market is primarily led by start-ups / small companies, such as (in alphabetical order) CellMax Life, Celsee Diagnostics, Datar Genetics, DiaDx, EONE-DIAGNOSTICS Genome Center, Exosome Sciences, iCellate Medical, Inivata, IVDiagnostics, LCM Genect and MDNA Life Sciences. It also has presence of mid to large-sized pharma players; notable examples include (in alphabetical order) Biocartis, Counsyl, Foundation Medicine, Genomic Health and NeoGenomic Laboratories. In addition to the aforementioned players, a number of pharma giants are also developing assets in this field. Prominent players under this category include (in alphabetical order) Affymetrix, Menarini Silicon Biosystems, Myriad Genetics, QIAGEN, Roche, Siemens Healthineers and ThermoFisher Scientific.
As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives of this report was to understand the future potential of the market. Amongst other elements, the report provides information on:
 The overall landscape of liquid biopsies and other novel non-invasive diagnostic tests with respect to the stage of development, type of markers (CTCs / ctNA / exosomes), test sample source (blood / urine / others), indications and type of application (early diagnosis / recurrence monitoring / patient monitoring). Additionally, the market overview highlights the geographical distribution and coverage of the tests across the globe, depicting the activity of this domain in different regions of the world.
 Comprehensive profiles of the popular tests and systems highlighting details on development status, specifications and advantages, clinical information, and related collaborations. Additionally, we have provided detailed profiles of the key players involved in the domain.
 The impact of venture capital funding in this area. It is important to mention that since the industry has witnessed the emergence of several start-ups, funding is a key enabler that is likely to drive both innovation and product development in the coming years.
 An elaborate valuation analysis of start-ups and small players that are involved in the liquid biopsy domain. We built a multi-variable dependent valuation model to estimate the current valuation of a number of companies focused in this domain.
 The emerging trends and the popularity of liquid biopsy on social media platforms, such as Twitter, over the last few years. The volume of tweets has witnessed an increasing trend in the last six years, influenced by the approval and launch of several liquid biopsy tests in the market.
 The competitive landscape of the players involved in the space. This is represented as an illustrative bubble analysis, which is based on parameters such as the liquid biopsy portfolio of a company, its number of employees and geographical coverage of the tests.
 Contribution of the other non-invasive cancer diagnostics market, taking into account the number of tests and the sales registered by the marketed tests.

In addition, we have provided a comprehensive market estimation to determine the global evolution of the liquid biopsy market. This has been done by evaluating the likely success of key applications of early diagnosis, recurrence monitoring and patient monitoring. We have included insights on the likely regional evolution of the market covering US, EU5 and rest of the world. In addition, we have estimated the likely contribution of different target patient populations to the global market; this covered key indications including (in alphabetical order) bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer. Further, we segmented the market by the type of markers (CTCs, ctNAs, exosomes) and the sample source (blood, urine, saliva) used in different liquid biopsies. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the time period 2017-2030. The conservative, base and optimistic scenarios represent three different tracks of the industry’s evolution. The research, analysis and insights presented in this report are backed by the deep understanding of key insights gathered from both secondary and primary research.

Our opinions and insights presented in this study were influenced by discussions that we conducted with several experts in this area. These included contributions from (in alphabetical order of companies) Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Frank Szczepanski (President and CEO, IVDiagnostics), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Nathalie Bernard (Marketing Director, OncoDNA), Abizar Lakdawalla (Founder, ProXeom), Mark Li (CEO, Resolution Bioscience) and Jake Micallef (Chief Scientific Officer, VolitionRx). All actual figures have been sourced and analyzed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. We identified over 110 liquid biopsy tests; of these, 60% of the tests are currently available for patients while the remaining are either available for research use only (RUO) or are under development. Further, of the total tests, 36% detect the presence of ctDNA in the sample, nearly 41% detect CTCs and 4% validate the presence of exosomes. Close to 19% of the liquid biopsy tests identify the presence of multiple / other markers.
2. It is worth highlighting that there are seven liquid biopsy tests that are being explored for use as companion diagnostics. Many partnerships have been inked to co-develop liquid biopsy companion diagnostic products; notable examples include collaborations between BMS and GRAIL (2017), Merck and Sysmex Inostics (2016), Biocept and Baylor College of Medicine (2015), QIAGEN and Tokai Pharmaceuticals (2015), ANGLE and MD Anderson Cancer Center (2015), and AstraZeneca and QIAGEN (2015).
3. Considering the future potential of these diagnostic kits and systems, several investors have made substantial capital commitment to drive future development. We identified approximately 196 funding instances amounting to capital investments (equity / debt / grants) of over USD 3.8 billion between 2011 and 2017; these investments were made either directly or indirectly to support the development of liquid biopsy products. In 2016 alone, driven by increased venture capital activity, amount worth USD 770 million was invested in different companies.
4. It is worth highlighting that with the rising activity in the field of cancer diagnostics, pharmaceutical players have been keen to explore the acquisition opportunities in this domain. In the Roots Analysis proprietary valuation analysis of over 40 start-ups / small companies, we identified nine companies that are likely to achieve valuation of over USD 500 million.
5. The market, primarily driven by the sales generated by liquid biopsy tests, is anticipated to register a growth rate of 19% between 2017 and 2030. The current market is dominated by the tests that offer patient monitoring (63% share). Specifically, catering to the high unmet need for timely treatment, the share of early diagnosis is likely to increase from 20% in 2017 to over 40% by 2030.
6. Among specific indications, we believe that prostate cancer is likely to capture the largest share of the market (~15%). Subsequently, owing to the large target patient population, breast cancer is likely to capture a share of 14% by 2030. In addition, lung cancer is also likely to capture a significant market share of 12% by 2030. It is worth highlighting that, despite the low prevalence of lung cancer, the demand of liquid biopsies is significantly high as tissue biopsy is extremely difficult in case of lungs.
7. With regard to the geographical activity, in 2017, the US is likely to capture the maximum share (43%) followed by EU5 (34%) and Rest of the World (RoW, 23%). The overall trend is unlikely to change significantly in 2030; however, regions in RoW are likely to occupy a larger share in 2030 (29%). It is important to highlight that, within RoW, Asian countries such as China, India, Japan, have several developers and distributors of liquid biopsy tests, demonstrating an elevating activity within these regions.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming 10-15 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.


CHAPTER OUTLINES
Chapter 2 presents an executive summary of the report. It offers a high level view on where the market for liquid biopsy and other novel non-invasive diagnostics is headed in the mid to long term.

Chapter 3 provides a general introduction to cancer statistics and the global burden of the disease. In this section, we have also highlighted the importance of early detection of the disease through diagnosis and asymptomatic screening. The chapter outlines the conventional invasive diagnostic tests, which are widely used for cancer diagnosis and prognosis.

Chapter 4 discusses, in detail, the need for non-invasive cancer diagnostics and their importance. We have highlighted the underlying concept of liquid biopsy and other non-invasive tests. In addition, we have mentioned the principle behind common imaging tests that are deployed in cancer diagnosis.

Chapter 5 provides a holistic view of the liquid biopsy market. It lists the liquid biopsy tests, technologies and systems. In addition, the chapter includes a detailed analysis of the liquid biopsy tests based on the development stage (available for patients / RUO / under development), sample type (blood / plasma / urine / multiple), type of markers detected (CTCs / ctNA (DNA) / exosomes / multiple / others), indication and type of application (early detection / patient monitoring / recurrence monitoring).

Chapter 6 offers an illustrative bubble analysis representing the competitive landscape of the players involved in the space, based on their liquid biopsy portfolio, number of employees and geographical coverage. In addition, it presents a Venn diagram depicting the distribution of liquid biopsy products across different application areas. The chapter elucidates the emerging trends and the popularity of liquid biopsy on social media platforms, such as Twitter, over the last few years.

Chapter 7 offers a comprehensive discussion on liquid biopsy. We have talked about the emerging need for liquid biopsy highlighting its advantages, and the related challenges. In addition, we have provided profiles of several liquid biopsy products and technologies. These products belong to those companies that were identified as active players in the bubble analysis presented in Chapter 6. The chapter also mentions the liquid biopsy companion diagnostics, which are being co-developed as part of strategic collaborations.

Chapter 8 presents details on the investments and grants received by companies working in the field of liquid biopsy. The analysis highlights the growing interest of the venture capital community and other strategic investors in this market.

Chapter 9 features a comprehensive valuation analysis of the companies that are developing liquid biopsy tests / technologies / systems / platforms / instruments. The chapter provides insights based on a multi-variable dependent valuation model. The model is based on the future potential of the companies’ uniqueness, their current popularity, funding received, year of establishment and the employed workforce.

Chapter 10 provides detailed company profiles of the leading players that are involved in the development of liquid biopsy tests. Amongst other details, each profile includes information such as the company overview, financial performance, product portfolio (technical specifications and clinical information) and recent collaborations.

Chapter 11 provides an overview of the other non-invasive diagnostics for oncology. It highlights different diagnostics tests, including non-blood based biomarker detection tests (saliva-based biomarker detection, stool-based metabolic biomarker detection, skin-based biomarker detection, semen-based biomarker detection and urine based biomarker detection), DNA methylation detection test, fecal occult blood test and fecal immunochemical test, MicroRNA (miRNA) based test, pigmented lesion assay, stool DNA (sDNA) testing, and Volatile Organic Compound (VOC) detection test. The diagnostic procedures discussed in this chapter are backed up by several examples. In addition, the chapter illustrates a detailed analysis on the survey conducted for gaining a deeper understanding on the nature of products and services offered by the companies.

Chapter 12 highlights the market forecast and sizing of the overall non-invasive cancer diagnostics market. This chapter discusses, in detail, the parameters that are likely to influence the evolution of liquid biopsy market. It features detailed insights on the likely market evolution for across different application areas such as early diagnosis, patient monitoring and recurrence monitoring. Additionally, the chapter presents a detailed market segmentation by the key indications, types of markers (CTCs, ctNAs, exosomes) and types of samples (blood, urine, saliva). The chapter also highlights the likely distribution of the market across the US, EU5 and RoW (including Asia) regions. We have also presented an informed view on the contribution of the other non-invasive tests in the overall non-invasive cancer diagnostics market.

Chapter 13 summarizes the overall report. In this chapter, we have listed the key takeaways and have provided our independent opinion based on the research and analysis described in previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the insights provided to us by Burkhard Jansen (Chief Medical Officer, DermTech), Christer Ericsson (Chief Scientific Officer, iCellate Medical), Frank Szczepanski (President and CEO, IVDiagnostics), Riccardo Razzini (Sales and Marketing Manager, LCM Genect), Philippe Nore (CEO and Co-founder, MiNDERA Corporation), Nathalie Bernard (Marketing Director, OncoDNA), Abizar Lakdawalla (Founder, ProXeom), Mark Li (CEO, Resolution Bioscience) and Jake Micallef (Chief Scientific Officer, VolitionRx)

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.

1. 10 MED
2. 360 Genomics
3. Abbott
4. Acadia Woods Partners
5. Accel Biotech
6. Accelerate Brain Cancer Cure
7. AccuraGen
8. Acecgt Life Science
9. Acer
10. Ackermans & van Haaren
11. Acousys Biodevices
12. AcuamarkDx
13. Adaptive Biotechnologies
14. Addario Lung Cancer Medical Institute (ALCMI)
15. Admera Health
16. AdnaGen
17. Aetna
18. Affymetrix
19. Agena Bioscience
20. Akademiska Hospital
21. Alexandria Venture Investments
22. Allegro Diagnostics
23. Allele Frequency Community
24. Allen & Company
25. Alliance Global
26. Alloy Ventures
27. Almac Group
28. Amadix
29. AME Cloud Ventures
30. America’s Choice Provider Network
31. American Association for Cancer Research
32. American Lung Association
33. American Society of Clinical Oncology
34. American Urological Association
35. AmeriHealth
36. Amgen
37. Amplitech
38. Andreessen Horowitz
39. Andros Mannenkliniek
40. ANGLE
41. Ann Arbor SPARK
42. Anpac Bio
43. ApoCell
44. Apollo Hospital
45. Appistry
46. ARCH Venture Partners
47. Arcus Ventures
48. Array BioPharma
49. Artiman Ventures
50. ARUP Laboratories
51. Aspire Capital Fund
52. Asset Management Ventures
53. Assurant
54. Astellas Pharma
55. Astia Angels
56. AstraZeneca
57. ATGen
58. Athena Advisors
59. Atlantic Cancer Research Institute
60. Attikon University Hospital
61. Aurelia Private Equity
62. Aurora Diagnostics
63. Aurum Ventures MKI
64. AVEO Oncology
65. AVIVA Biosciences
66. AXON Dx
67. Ballast Point Ventures
68. Barts Cancer Institute
69. Bayer Healthcare
70. Baylor College of Medicine
71. BC Biomedical Laboratories
72. BC Cancer Agency
73. Becton Dickinson
74. Benaruca
75. Betta Pharmaceuticals
76. BGI Tech Solutions
77. Bio.be
78. Biocartis
79. Biocept
80. Biodesix
81. BioFluidica
82. Biogen
83. Biognosys
84. Biohit HealthCare
85. Biological Dynamics
86. BioMark Diagnostics
87. bioMerieux
88. Bio-Rad
89. BioSense Medical
90. Biosensors International
91. Biotron Healthcare
92. Biotype Diagnostics
93. BioVeda
94. BioVendor
95. Biovest
96. Bioyong Technology Company
97. Birla Sun Life Insurance
98. Blair Gastroenterology Associates
99. Blisce
100. Blue Cross and Blue Shield of Illinois
101. Blue Cross and Blue Shield of Louisiana
102. Blue Cross Blue Shield of Michigan
103. Blue Ridge Capital
104. Boreal Genomics
105. Brand Capital
106. Brandenburg Capital (BFBII)
107. Breast Care Centre - Jefferson Health
108. Breathtec Biomedical
109. Brigham and Women's Hospital
110. Bristol-Myers Squibb
111. Cadence Bank
112. Cahaba Government Benefit Administrators
113. Cambridge Innovation Capital
114. Cambridge Oncometrix
115. Cancer Genetics
116. Canopus Bioscience
117. Capio Biosciences
118. Capital Health Plan
119. Capital Royalty Partners
120. CareFirst
121. Caris Life Sciences
122. Casdin Capital
123. Catholic Health Initiatives Centre for Translational Research
124. CD Ventures
125. CDBI Partners
126. CeGaT
127. CellMax Life
128. Celsee Diagnostics
129. Centro di Ricerche Oncologiche di Mercogliano (CROM)
130. Cerba HealthCare
131. Charles River Associates
132. Cigna
133. Circulogene Theranostics
134. City of Hope Medical Center
135. CKM Capital Partners
136. Claremont Creek Ventures
137. Clarient
138. Clearbridge BioMedics
139. Clearbridge BSA
140. Clinical and Experimental Pharmacology Group, The University of Manchester
141. Clinical Genomics
142. CloudHealth Genomics
143. Clovis Oncology
144. CollabRx
145. College of American Pathologists
146. Color
147. Columbia University
148. Concentra
149. CORE Diagnostics
150. COTA Partners
151. Counsyl
152. Creatv MicroTech
153. Crede Capital Group
154. Cynvenio Biosystems
155. CytoLumina Technologies
156. CytoTrack
157. Dana-Farber Cancer Institute
158. Data Collective
159. Datar Genetics
160. DDL Diagnostic Laboratory
161. Debiopharm Group
162. Decheng Capital
163. Deerfield Capital Management
164. Department of Biopathology, Institut de Cancérologie de Lorraine (ICL)
165. Department of Oncology, Vejle Hospital
166. Department of Urology, Radboud University Medical Center
167. DermTech
168. DiaDx
169. DiagnoCure
170. Diagnologix
171. Diagnostica Longwood
172. Diffusion Capital Partners
173. Domain Associates
174. Dr Lal PathLabs
175. Dr. Rosell Oncology Institute
176. Drug Response Dx
177. DSP BlackRock
178. DT Capital Partners
179. Dynacare
180. Eastern Cooperative Oncology Group
181. Edison Innovation VC Growth Fund
182. EKF Molecular Diagnostics
183. Eli Lilly
184. EmblemHealth
185. Emerge Venture
186. EONE-DIAGNOMICS Genome Center
187. Epic Sciences
188. Epigenomics
189. Epistem Pharmacogenomics
190. Eta Diagnostics
191. EUREKA
192. European Medical Network for Translational Research in Ovarian Cancer (EUTROC)
193. European Research Organization on Genital Infection and Neoplasia (EUROGIN)
194. European Society for Medical Oncology
195. Exact Sciences
196. Exalenz Bioscience
197. Exosome Diagnostics
198. Exosome Sciences
199. Exosomics Siena
200. Fairview Health Services
201. Federal Holding and Investment Company
202. FedMed
203. Felicis Ventures
204. Fidelity Investments
205. First Coast Service Options
206. Flatiron Health
207. Flemish Agency for Innovation & Entrepreneurship
208. Florida Blue
209. Fluxion Biosciences
210. Forbion Capital Partners
211. Formation 8
212. Fortified Provider Network
213. Foundation Medicine
214. Franklin Synergy Bank
215. Franklin Templeton Investments
216. Fraunhofer Institute for Cell Therapy and Immunology
217. Galaxy Health Network
218. GATC Biotech
219. GBP Scientific
220. GE Ventures
221. Genetic Technologies
222. Genomac Research Institute
223. Genomic Health
224. Genomictree
225. Genoptix
226. Genostics
227. GenSignia
228. Gentris
229. Georgetown Lombardi Comprehensive Cancer Center
230. GILUPI
231. Goldman Sachs Asset Management
232. Google Ventures
233. GRAIL
234. Green Pine Capital Partners
235. Greenwoods Private Equity Funds
236. Group Health Cooperative
237. Guardant Health
238. Hancock Bank
239. HarlePhil Ventures, Harle Group
240. Harmony Partners
241. Health Alliance Plan
242. Health Canada
243. Health Care Services Corporation
244. Health Net
245. HealthCor Partners Management
246. Hemosure
247. Heritage Group
248. HIFU CLINIC Prostate Cancer Treatment Center
249. Highmark
250. High-Tech Gründerfonds
251. Hitachi Chemical Diagnostics
252. Hitachi High-Technologies Corporation
253. Hologic
254. Hooper Holmes Health and Wellness
255. Horizon Blue Cross Blue Shield of New Jersey
256. HTG Molecular Diagnostics
257. Humana
258. Hygieia Sciences
259. IBM Watson
260. iCellate Medical
261. ICICI Prudential
262. Illumina
263. Imperial Innovations
264. Incyte
265. Independence BlueCross
266. IndivuTest
267. Inivata
268. Innogene Kalbiotech
269. Innovation Endeavors
270. Inserm Transfert
271. Insight Genetics
272. Instituto Diagnostico Varelli
273. Integrated Personalize Medicine
274. Interpace Diagnostics
275. Inventures
276. IPS Genomix
277. IVDiagnostics
278. Janssen Diagnostics
279. Sidney Kimmel Cancer Center, Thomas Jefferson University
280. Jennison Associates
281. Johns Hopkins University School of Medicine
282. Johnson & Johnson Development Corporation
283. Johnson & Johnson Innovation
284. JoyingBio
285. JP Morgan Chase
286. Junson Capital
287. Kadmon Corporation
288. Kaiser Permanente
289. Karolinska Institute
290. KBC Bank
291. Kearny Venture Partners
292. KfW Bankengruppe
293. Khosla Ventures
294. Kleiner Perkins Caufield & Byers
295. KMD Biomarker Diagnostics
296. Kodiak Venture Partners
297. Koninklijke Philips
298. Korys
299. Kotak Mahindra Bank
300. Lab21
301. Labco Quality Diagnostics
302. LabCorp
303. LabsMD
304. Lakeshore ArchAngels
305. Lantern Pharma
306. LCM Genect
307. LifeLabs
308. Lightspeed Venture Partners
309. Lilly Asia Ventures
310. Liquid Biotech USA
311. Livzon Pharmaceutical Group
312. London Health Sciences Centre
313. Louisiana State University
314. Manipal Group
315. Martinské bioptické centrum
316. Massachusetts General Hospital
317. Massey Cancer Centre
318. Mayo Clinic
319. Mayo Medical Laboratory
320. MD Anderson Cancer Center
321. MDNA Life Sciences
322. MDxHealth
323. MedGenome
324. Medical Mutual of Ohio
325. Medical University of Vienna
326. MediLabs
327. MedImmune
328. MedSIR
329. MedStar Georgetown University Hospital
330. MedX Health
331. MELA Sciences
332. Memorial Sloan Kettering Cancer Center
333. Menarini Silicon Biosystems
334. Menssana Research
335. Merck
336. Merrill Lynch
337. Metabiomics
338. Metabolomic Technologies
339. Metabolomx
340. MetaCell
341. Michael J. Fox Foundation
342. Mikro Biyosistemler
343. Milenia Labs
344. MiNDERA
345. Ministry of Health, Labour and Welfare, Japan
346. Mirati Therapeutics
347. Miroculus
348. MiRXES
349. MLabs, University of Michigan
350. Mohr Davidow Ventures
351. Molecular Pathology Laboratory Network
352. MolecularMD
353. Monashee Capital
354. mtm laboratories
355. MultiPlan
356. Multiplicom
357. Münchner Leukämie Labor (MLL)
358. Myriad Genetics
359. Nan Fung Group
360. Nanjing Kaiyuan Growth Capital Investments
361. NASA
362. Natera
363. National Cancer Institute, US
364. National Cancer Research Institute, UK
365. National Comprehensive Cancer Network, US
366. National Government Services, US
367. National Institutes of Health, US
368. Nektar Therapeutics
369. NEO New Oncology
370. NeoGenomics Laboratories
371. Neuberger Berman Group
372. New Enterprise Associates
373. New Jersey Economic Development Authority
374. New Rhein Healthcare
375. NGen Partners
376. NGN Capital
377. NM Genomix
378. Nodexus
379. Norgen Biotek
380. Noridian,
381. Palmetto GBA
382. Northgate Capital
383. Northwestern University
384. Novartis
385. NovioGendix
386. Novitas Solutions
387. NuGen
388. Olivia Newton-John Cancer Centre
389. Oncimmune
390. OncoCyte Corporation
391. OncoDNA
392. Oncolys Biopharma
393. OneVentures
394. OrbiMed Advisors
395. Ortho Biotech Oncology Research & Development
396. Owlstone Medical
397. Oxford Finance Corporation
398. Pacific Edge
399. Palapa Ventures
400. Palex Medical
401. Pangaea Biotech
402. Papillon Capital
403. Participatiemaatschappij Vlaanderen
404. PathQC
405. Pathway Genomics
406. Pejman Mar Ventures
407. Perelman School of Medicine, University of Pennsylvania
408. PeriRx
409. Personal Genome Diagnostics
410. Pfizer
411. Pfizer Venture Investments
412. Phenomenome Discoveries
413. Philips
414. Philips Research
415. Picomole Instruments
416. Pilot Growth Equity
417. Pink Lotus Breast Cancer
418. PMV Tina Fund
419. PNC Bank
420. Polaris Partners
421. Polymedco
422. PrairieGold Venture Partners
423. Predicine
424. PreferredOne
425. Premier
426. Prime Genomics
427. Prime Value Capital Management
428. Principia Biopharma
429. Priority Health Michigan
430. Progenetics
431. Promega Corporation
432. Prostate Cancer Foundation
433. ProXeom
434. Pulmostics
435. QIAGEN
436. Quaker BioVentures
437. Queen Mary University
438. Quest Diagnostics
439. RA Capital Management
440. RainDance Technologies
441. Rarecells Diagnostics
442. RareCyte
443. Redmile Group
444. Regenerus Laboratories
445. Regions Capital Markets
446. Reliance Capital
447. Research Genetic Cancer Centre (R.G.C.C.) Group
448. Resolution Bioscience
449. Response Genetics
450. RMI Partners
451. Robert H. Lurie Comprehensive Cancer Center, Northwestern University
452. Roche
453. Roche Venture Fund
454. Rosemont Seneca Technology Partners
455. Rosetta Genomics
456. Roswell Park Cancer Institute
457. Royal Philips Electronics
458. SAGA Diagnostics
459. SAIC-Frederick
460. SMBRINVEST
461. Samsung Medical Center
462. San Antonio Military Medical Center
463. Sanomics
464. Sarah Cannon Research Institute (SCRI)
465. ScheBo Biotech
466. ScreenCell
467. Seaside National Bank and Trust
468. Sectoral Asset Management
469. Selah Genomics
470. Sequenom
471. Sequoia Capital
472. Shanghai Zhangjiang Science & Technology Investment Corporation (ZJSTIC)
473. Siemens Healthcare Diagnostics
474. Silicon Valley Bank
475. SIMSYS
476. Singlera Genomics
477. Singulex
478. Sividon Diagnostics
479. SkyDeck
480. Skyline Diagnostics
481. Société Régionale d'Investissement de Wallonie
482. Sofinim
483. Sofinnova Ventures
484. Sorgente Genetica
485. SouthGenetics
486. Southwest Oncology Group
487. Spanish Ministry of Economy and Competitiveness (MINECO)
488. Spectrum 28
489. SPRING Seed Capital
490. SRI International
491. St. Louis Arch Angels
492. StableBody Technologies
493. Stanford-StartX Fund
494. State Bank of India
495. Strand Life Sciences
496. STRATA Skin Sciences
497. Stratose
498. Streck
499. Sungent Bioventure
500. Sutter Hill Ventures
501. SYGNIS
502. Synlab Group
503. Syno Capital
504. Sysmex Corporation
505. Sysmex Inostics
506. T Rowe Price
507. Takeda Pharmaceuticals
508. Technion-Israel Institute of Technology
509. Telegraph Hill Partners (THP)
510. TEM Research
511. Temasek Holdings
512. Teneovita Medical Innovations
513. Teva Pharmaceuticals
514. The eNose Company
515. The European Health Centre Innovation (EHC Innovation)
516. The Huntington National Bank
517. The Institute of Cancer Research
518. The Pancreatic Cancer Action Network
519. The University of Manchester
520. The University of Michigan Comprehensive Cancer Center
521. The Wistar Institute
522. Therawis Diagnostics
523. Thermo Fisher Scientific
524. Third Kind Venture Capital
525. Third Rock Ventures
526. Third Security
527. Thomas Jefferson University
528. Three Rivers Provider Network
529. thromboDx
530. Tiger Management
531. Tokai Pharmaceuticals
532. Transgenomic
533. Trovagene
534. Tumor Bank Ovarian Cancer Network
535. Ucare
536. United HealthCare
537. UnitedHealth Group
538. Universitätsklinikum Knappschaftskrankenhaus Bochum
539. University Hospital Brussels
540. University Medical Centre Hamburg-Eppendorf
541. University of Athens
542. University of British Columbia
543. University of California, Los Angeles
544. University of California, San Diego
545. University of California, San Francisco
546. University of Colorado, Anschutz Medical Campus
547. University of Duisburg-Essen
548. University of Dusseldorf
549. University of Melbourne
550. University of Michigan
551. University of Pennsylvania
552. University of Rochester Medical Center
553. University of Southern California (USC) Norris Comprehensive Cancer Centre
554. University of Southern Denmark
555. University of Texas
556. Uppsala BIO
557. US Oncology Research (USOR)
558. US Preventive Services Task Force
559. Valiance
560. Vall d'Hebron Institute of Oncology
561. Vancouver Prostate Centre
562. Velox Biosystems
563. Ventana Medical Systems
564. Veridex
565. Vertex Venture Holdings
566. Viatar CTC Solutions
567. Vinsovier
568. Virginia Commonwealth University
569. Vitatex
570. VolitionRx
571. Vortex Bioscience
572. VU University Medical Center
573. VWR International
574. VyCAP
575. WaveSense
576. Wellcome Trust Sanger Institute
577. Wellmark Blue Cross Blue Shield
578. Wells Fargo Securities
579. Wilmot Cancer Intitute, Uiverity of Rochester Medical Center
580. Windham Venture Partners
581. Wisconsin Physician Services
582. Woodford Patient Capital Trust
583. Wren Laboratories
584. Yale University
585. Yissum Research Development Company


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Cancer Statistics and Burden of the Disease
3.3. Importance of Early Detection in Cancer
3.4. Detecting Cancer: Screening vs. Diagnosis
3.5. Conventional Invasive Cancer Diagnostic Tests
3.5.1. Biopsy
3.5.1.1. Fine Needle Aspiration Biopsy
3.5.1.2. Core Needle Biopsy
3.5.1.3. Vacuum-Assisted Biopsy
3.5.1.4. Image-Guided Biopsy
3.5.1.5. Sentinel Node Biopsy
3.5.1.6. Surgical Biopsy
3.5.1.7. Endoscopic Biopsy
3.5.1.8. Bone Marrow Biopsy
3.5.2. Endoscopy
3.6. Need for Non-Invasive Approaches
3.7. Costs and Benefits Associated with Non-Invasive Tests
4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS
4.1. Chapter Overview
4.2. Diagnostic Imaging
4.2.1. Magnetic Resonance Imaging (MRI)
4.2.2. Mammography
4.2.3. Bone Scan
4.2.4. Computerized Tomography (CT) Scan
4.2.5. Integrated PET-CT Scan
4.2.6. Ultrasound
4.2.7. Barium Enema
4.3. Screening Assays
4.3.1. Papanicolaou Test (Pap Test) and Human Papilloma Virus Test (HPV Test)
4.3.2. Tumor Marker Test
4.3.3. Fecal Occult Blood Tests (FOBT)
4.3.4. Digital Rectal Exam (DRE)
4.3.5. Multigated Acquisition (MUGA) Scan
4.4. Advanced Non-Invasive Approaches
4.4.1. Liquid Biopsy
4.4.2. Cytogenetic / Gene Expression Studies
4.4.3. Molecular Signature Based Non-Invasive Methods
4.4.4. Saliva-Based Oral Cancer Diagnostics
4.4.5. Vital Staining
4.4.6. Optical Biopsy
4.4.7. Other Techniques
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Liquid Biopsy: Development Landscape
5.2.1. Liquid Biopsy Tests: Distribution by Development Stage
5.2.2. Liquid Biopsy Tests: Distribution by Sample Type
5.2.3. Liquid Biopsy Tests: Distribution by Type of Markers Detected
5.2.4. Liquid Biopsy Tests: Distribution by Indication
5.2.5. Liquid Biopsy Tests: Distribution by Type of Application
5.2.6. Liquid Biopsy Tests: Distribution by Geographical Coverage
5.2.7. Liquid Biopsy Tests: Distribution by Leading Players
5.3. Liquid Biopsy: Technologies, Platforms, Systems and Instruments
6. LIQUID BIOPSY MARKET: KEY INSIGHTS
6.1. Chapter Overview
6.2. Liquid Biopsy Tests: Competitive Landscape of Developers
6.3. Liquid Biopsy Tests: Distribution by Application and Target Indications
6.4. Emerging Trends on Non-Invasive Cancer Diagnostics on Social Media
6.4.1. Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016)
6.4.2. Non-Invasive Cancer Diagnostics: Twitter Word Cloud (2010, 2012, 2014, 2016)
6.4.3. Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016)
6.4.4. Non-Invasive Cancer Diagnostics: Twitter Trends for Samples Types (2010-2016)
7. LIQUID BIOPSY: DETAILED OUTLOOK
7.1. Chapter Overview
7.2. Non-Invasive Methods Over Biopsies for Detection of Cancer
7.3. Circulating Biomarkers for Cancer
7.3.1. Circulating Tumor Cells (CTCs)
7.3.1.1. Advantages Associated with the Use of CTCs
7.3.1.2. Challenges Associated with the Use of CTCs
7.3.2. Circulating Tumor DNA (ctDNA)
7.3.3. Exosomes
7.4. Liquid Biopsy Based Tests and Systems
7.4.1. BioFluidica CTC Isolation Technology, CTC Analysis System and Test, BioFluidica / Roche
7.4.1.1. Overview
7.4.1.2. Specifications and Advantages
7.4.1.3. Clinical Information
7.4.1.4. Collaborations
7.4.2. CancerIntercept™ Detect and CancerIntercept™ Monitor, Pathway Genomics
7.4.2.1. Overview
7.4.2.2. Specifications and Advantages
7.4.2.3. Clinical Information
7.4.2.4. Collaborations
7.4.3. Cancertrack, Datar Genetics
7.4.3.1. Overview
7.4.3.2. Specifications and Advantages
7.4.3.3. Clinical Information
7.4.3.4. Collaborations
7.4.4. CellMax-LBx Liquid Biopsy and CellMax-CRC Colorectal Cancer Blood Test, CellMax Life
7.4.4.1. Overview
7.4.4.2. Specifications and Advantages
7.4.4.3. Clinical Information
7.4.4.4. Collaborations
7.4.5. CELLSEARCH® System and CELLSEARCH® CTC Test, Menarini Silicon Biosystems
7.4.5.1. Overview
7.4.5.2. Specifications and Advantages
7.4.5.3. Clinical Information
7.4.5.4. Collaborations
7.4.6. cobas® EGFR Mutation Test v2, Roche
7.4.6.1. Overview
7.4.6.2. Specifications and Advantages
7.4.6.3. Clinical Information
7.4.6.4. Collaborations
7.4.7. LiquidBiopsy® Rare Cell Isolation Platform, ClearID® Total Insight Breast Cancer, ClearID® Lung Cancer and Clear ID® Melanoma, Cynvenio Biosystems
7.4.7.1. Overview
7.4.7.2. Specifications and Advantages
7.4.7.3. Clinical Information
7.4.7.4. Collaborations
7.4.8. Oncocount, Oncotrace, Oncotrial and Metastat, R.G.C.C. Group
7.4.8.1. Overview
7.4.8.2. Specifications and Advantages
7.4.8.3. Clinical Information
7.4.9. OncoBEAM™ CRC RAS Kit, Sysmex Inostics / Merck
7.4.9.1. Overview
7.4.9.2. Specifications and Advantages
7.4.9.3. Clinical Information
7.4.9.4. Collaborations
7.4.10. OnTarget™ Assay, Boreal Genomics
7.4.10.1. Overview
7.4.10.2. Specifications and Advantages
7.4.10.3. Clinical Information
7.4.10.4. Collaborations
7.4.11. PrediSeq-Prostate and PrediSeq-Lung, Predicine
7.4.11.1. Overview
7.4.11.2. Specifications and Advantages
7.4.11.3. Clinical Information
7.4.11.4. Collaborations
7.4.12. SelectMDx™, MDxHealth
7.4.12.1. Overview
7.4.12.2. Specifications and Advantages
7.4.12.3. Clinical Information
7.4.12.4. Collaborations
7.4.13. ViewRNA™ CTC Platform and Assay, Affymetrix
7.4.13.1. Overview
7.4.13.2. Specifications and Advantages
7.4.13.3. Collaborations
7.4.14. Velox™, IVDiagnostics
7.4.14.1. Overview
7.4.14.2. Collaborations
7.4.15. ApoStream® System and Technology, ApoCell
7.4.15.1. Overview
7.4.15.2. Specifications and Advantages
7.4.15.3. Clinical Information
7.4.15.4. Collaborations
7.4.16. IsoPic™, iCellate Medical
7.4.16.1. Overview
7.4.16.2. Specifications and Advantages
7.4.16.3. Clinical Information
7.4.16.4. Collaborations
7.4.17. Parsortix™ System, ANGLE
7.4.17.1. Overview
7.4.17.2. Specifications and Advantages
7.4.17.3. Clinical Information
7.4.17.4. Collaborations
7.5. Companion Liquid Biopsies: Recent Developments
7.5.1. Biocept and Baylor College of Medicine
7.5.2. Tokai Pharmaceuticals and QIAGEN
7.5.3. ANGLE and MD Anderson Cancer Center
7.5.4. AstraZeneca and QIAGEN
7.5.5. Sysmex Inostics and Bayer Healthcare
8. VENTURE CAPITAL FUNDING
8.1. Chapter Overview
8.2. Types of Funding
8.3. Liquid Biopsy Market: Funding Instances, 2011-2017
8.4. Liquid Biopsy Market: Distribution by Year
8.5. Liquid Biopsy Market: Distribution of Type of Model
8.6. Leading Players: Distribution by Funding Instances
9. COMPANY VALUATION ANALYSIS
9.1. Chapter Overview
9.2. Company Valuation: Methodology
9.3. Company Valuation: Categorization by Multiple Parameters
9.3.1. Categorization by Google Hits Score
9.3.2. Categorization by Awards Score
9.3.3. Categorization by Twitter Score
9.3.4. Categorization by Twitter Followers Score
9.3.5. Categorization by Number of Products
9.3.6. Categorization by Uniqueness Score
9.3.7. Categorization by Weighted Average Score
9.4. Company Valuation: Roots Analysis Proprietary Scores
10. LIQUID BIOPSY: KEY PLAYERS
10.1. Chapter Overview
10.2. Biocartis
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Portfolio
10.2.3.1. Idylla™ ctBRAF Mutation Assay (RUO)
10.2.3.2. Idylla™ ctKRAS Mutation Assay
10.2.3.3. Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO)
10.2.4. Collaborations
10.3. Biocept
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Portfolio
10.3.3.1. Target Selector™ Breast Cancer Test
10.3.3.2. Target Selector™ Lung Cancer Test
10.3.3.3. Target Selector™ Immuno-Oncology PD-L1 Test
10.3.3.4. Target Selector™ Gastric Cancer Test
10.3.3.5. Target Selector™ Colorectal Cancer Test
10.3.3.6. Target Selector™ Prostate Cancer Test
10.3.3.7. Target Selector™ Melanoma Test
10.3.4. Collaborations
10.4. Biodesix
10.4.1. Company Overview
10.4.2. Financial Information
10.4.3. Product Portfolio
10.4.3.1. GeneStrat®
10.4.3.2. VeriStrat®
10.4.4. Collaborations
10.5. Exosome Diagnostics
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Product Portfolio
10.5.3.1. ExoDx™ Prostate (IntelliScore)
10.5.3.2. ExoDx™ Lung (ALK)
10.5.3.3. ExoDx™ Lung (EGFR/T790M)
10.5.3.4. ExoDx™ Solid Tumor
10.5.4. Collaborations
10.6. Genomic Health
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Portfolio
10.6.3.1. Oncotype SEQ™ Liquid Select
10.6.4. Collaborations
10.7. Guardant Health
10.7.1. Company Overview
10.7.2. Financial Information
10.7.3. Product Portfolio
10.7.3.1. Guardant360™
10.7.4. Collaborations
10.8. NeoGenomics Laboratories
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Portfolio
10.8.3.1. NeoLAB™ HEME
10.8.3.2. NeoLAB™ Solid Tumor Monitor (NeoLAB SOLID TUMOR)
10.8.3.3. NeoLAB™ Prostate
10.8.3.4. NeoLAB™ EGFR T790M Liquid Biopsy
10.8.4. Clinical Information
10.8.5. Collaborations
10.9. Personal Genome Diagnostics (PGDx)
10.9.1. Company Overview
10.9.2. Financial Information
10.9.3. Product Portfolio
10.9.3.1. MetDETECT™
10.9.3.2. PlasmaSELECT™ R 64
10.9.3.3. LungSELECT™
10.9.4. Collaborations
10.10. QIAGEN
10.10.1. Company Overview
10.10.2. Financial Performance
10.10.3. Product Portfolio
10.10.3.1. AdnaTest Technology (Acquired from AdnaGen)
10.10.3.2. therascreen® EGFR RGQ PCR Kit
10.10.3.3. Sample Preparation Kits
10.10.4. Collaborations
10.11. Transgenomic
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. Product Portfolio
10.11.3.1. MX-ICP CRC Analysis
10.11.3.2. MX-ICP Melanoma Analysis
10.11.3.3. MX-ICP NSCLC Analysis
10.11.4. Collaborations
10.12. Trovagene
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. Product Portfolio
10.12.3.1. Trovera™ BRAF Mutation Detection
10.12.3.2. Trovera™ EGFR Mutation Detection
10.12.3.3. KRAS Mutation Detection
10.12.3.4. HPV HR Detection Test
10.12.4 Collaborations
11. OTHER NON-INVASIVE CANCER DIAGNOSTICS
11.1. Chapter Overview
11.2. Non-Blood Based Biomarker Detection Tests
11.3. DNA Methylation Detection Tests
11.4. Fecal Occult Blood Test (FOBT) AND Fecal Immunochemical Test (FIT)
11.5. MicroRNA (miRNA) Based Test
11.6. Pigmented Lesion Assay
11.7. Stool DNA (sDNA) Testing
11.8. Volatile Organic Compound (VOC) Detection Test
11.9. Other Non-Invasive Cancer Diagnostics: Market Landscape
11.10. Other Non-Invasive Cancer Diagnostics: Survey Analysis
11.10.1. Survey Analysis: Seniority Level of Respondents
11.10.2. Survey Analysis: Type of Product Portfolio
11.10.3. Survey Analysis: Types of Products / Services Offered
11.10.4. Survey Analysis: Type of Application
11.10.5. Survey Analysis: Availability of the Products
11.10.6. Survey Analysis: Likely Market Size
12. MARKET SIZING AND FORECAST
12.1. Chapter Overview
12.2. Forecast Assumptions and Methodology
12.3. Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030
12.3.1. Liquid Biopsy Market Forecast, 2017-2030
12.3.1.1. Liquid Biopsy Market Forecast: Distribution by Application
12.3.1.2. Liquid Biopsy Market Forecast: Distribution by Indication
12.3.1.3. Liquid Biopsy Market Forecast: Distribution by Type of Marker
12.3.1.4. Liquid Biopsy Market Forecast: Distribution by Type of Sample
12.3.1.5. Liquid Biopsy Market Forecast: Distribution by Geography
12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030
13. CONCLUSION
13.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology
13.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management
13.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis
13.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications
13.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies
13.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation
13.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential
13.8. Primarily Led by Liquid Biopsy, The Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market
14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. Burkhard Jansen, MD, Chief Medical Officer, DermTech
14.3. Frank Szczepanski, President and CEO, IVDiagnostics
14.4. Riccardo Razzini, Sales and Marketing Manager, LCM Genect
14.5. Nathalie Bernard, Marketing Director, OncoDNA
14.6. Abizar Lakdawalla, Founder, ProXeom
14.7. Mark Li, CEO, Resolution Bioscience
14.8. Christer Ericsson, Chief Scientific Officer, iCellate Medical
14.9. Philippe Nore, CEO and Co-founder, MiNDERA
14.10. Jake Micallef, Chief Scientific Officer, VolitionRx
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Worldwide Incidence of Cancer: Distribution by Type
Figure 3.2 Lung Cancer: Estimated New Cases in 2016 (In Thousands)
Figure 3.3 Breast Cancer: Estimated New Cases in 2016 (In Thousands)
Figure 3.4 Colorectal Cancer: Estimated New Cases in 2016 (In Thousands)
Figure 3.5 Factors Determining Useful Cancer Screening
Figure 3.6 Conventional Cancer Diagnosis Methods
Figure 3.7 Disadvantages of Conventional Cancer Diagnosis Methods
Figure 3.8 Traditional Biopsy: Process Flow
Figure 3.9 Non-Invasive Biopsy: Process Flow
Figure 4.1 Broad Categories of Non-Invasive Cancer Screening and Diagnostics
Figure 4.2 Types of Diagnostic Imaging
Figure 4.3 Types of Screening Assays
Figure 4.4 Types of Advanced Non-Invasive Approaches
Figure 5.1 Liquid Biopsy Tests: Distribution by Development Stage
Figure 5.2 Liquid Biopsy Tests: Distribution by Sample Type
Figure 5.3 Liquid Biopsy Tests: Distribution by Type of Markers Detected
Figure 5.4 Liquid Biopsy Tests: Distribution by Indication
Figure 5.5 Liquid Biopsy Tests: Distribution by Type of Application
Figure 5.6 Liquid Biopsy Tests: Distribution by Leading Players
Figure 6.1 Liquid Biopsy Competitive Landscape: Established Players
Figure 6.2 Liquid Biopsy Competitive Landscape: Mid-Sized Players
Figure 6.3 Liquid Biopsy Competitive Landscape: Start-ups
Figure 6.4 Liquid Biopsy Tests (Available for Patients): Distribution by Application and Target Indications
Figure 6.5 Liquid Biopsy Tests (Available for RUO / Under Development): Distribution by Application and Target Indications
Figure 6.6 Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016)
Figure 6.7 Non-Invasive Cancer Diagnostics: Twitter World Cloud (2010, 2012, 2014, 2016)
Figure 6.8 Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016)
Figure 6.9 Non-Invasive Cancer Diagnostics: Twitter Trends for Sample Type (2010-2016)
Figure 7.1 Circulating Biomarkers for Cancer Detection
Figure 7.2 BioFluidica CTC Isolation System: Steps of Operation
Figure 7.3 BioFluidica CTC Isolation System: Advantages
Figure 7.4 CellMax’s Liquid Biopsy: Steps of Operation
Figure 7.5 CELLSEARCH® System: Steps of Operation
Figure 7.6 cobas® EGFR Mutation Test v2: Steps of Operation
Figure 7.7 LiquidBiopsy® Rare Cell Isolation Platform: Steps of Operation
Figure 7.8 LiquidBiopsy® Rare Cell Isolation Platform and Ion Torrent™ PGM Workflow Components
Figure 7.9 OnTarget™ Assay: Steps of Operation
Figure 7.10 PrediSeq: Steps of Operation
Figure 7.11 ViewRNA™ CTC Platform: Steps of Operation
Figure 7.12 Apostream® Technology: Advantages
Figure 7.13 IsoPic™ Instrument: Steps of Operation
Figure 7.14 Parsortix™ System: Steps of Operation
Figure 8.1 Liquid Biopsy Market: Cumulative Funding Instances, 2011-2017
Figure 8.2 Liquid Biopsy Market: Cumulative Funding Amount, 2011-2017 (USD Billion)
Figure 8.3 Liquid Biopsy Market: Distribution by Type of Funding Instances, 2011-2017
Figure 8.4 Liquid Biopsy Market: Distribution by Total Amount Invested, 2011-2017 (USD Billion)
Figure 8.5 Liquid Biopsy Market: Distribution by Amount Invested and Type of Funding (USD Billion)
Figure 8.6 Leading Players: Distribution by Number of Funding Instances
Figure 9.1 Company Valuation Analysis: A/F Ratio, Input Dataset
Figure 9.2 Company Valuation Analysis: A/Y Ratio, Input Dataset
Figure 9.3 Company Valuation Analysis: A/E Ratio, Input Dataset
Figure 9.4 Company Valuation Analysis: Categorization by Google Hits Score
Figure 9.5 Company Valuation Analysis: Categorization by Awards Score
Figure 9.6 Company Valuation Analysis: Categorization by Tweets Score
Figure 9.7 Company Valuation Analysis: Categorization by Twitter Followers Score
Figure 9.8 Company Valuation Analysis: Categorization by Number of Products
Figure 9.9 Company Valuation Analysis: Categorization by Uniqueness Score
Figure 9.10 Company Valuation Analysis: Categorization by Weighted Average Score
Figure 9.11 Company Valuation Analysis: Unicorns in Liquid Biopsy
Figure 10.1 Biocartis: Annual Revenues, 2012-2016 (EUR Million)
Figure 10.2 Idylla™: Steps of Operation
Figure 10.3 Biocept: Annual Revenues, 2012-2016 (USD Million)
Figure 10.4 Biodesix Lung Reflex Test: Steps of Operation
Figure 10.5 GeneStrat®: Clinical Validation Data
Figure 10.6 Genomic Health: Annual Revenues, 2010-2016 (USD Million)
Figure 10.7 Guardant360™: Steps of Operation
Figure 10.8 NeoGenomics Laboratory: Annual Revenues, 2010-2016 (USD Million)
Figure 10.9 NeoLAB™ Prostate: Steps of Operation
Figure 10.10 PlasmaSELECT™ R64: Steps of Operations
Figure 10.11 QIAGEN: Annual Revenues, 2010–2016 (USD Billion)
Figure 10.12 QIAGEN Sales, 2016: Distribution by Business Segments
Figure 10.13 Transgenomic: Annual Revenues, 2010 – Q1-Q3 2016 (USD Million)
Figure 10.14 ICEme Kit: Steps of Operation
Figure 10.15 Trovagene: Annual Revenues, 2010–2016 (USD Million)
Figure 11.1 Survey Analysis: Distribution by Geography
Figure 11.2 Survey Analysis: Seniority Levels of Respondents
Figure 11.3 Survey Analysis: Distribution by Type of Product Portfolio
Figure 11.4 Survey Analysis: Distribution by Type of Products / Services Offered
Figure 11.5 Survey Analysis: Distribution by Type of Application
Figure 11.6 Survey Analysis: Distribution by Availability of the Products
Figure 11.7 Survey Analysis: Likely Liquid Biopsy Market Size (2030)
Figure 11.8 Survey Analysis: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
Figure 12.1 Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
Figure 12.2 Liquid Biopsy Market (2017-2030): Base Scenario (USD Billion)
Figure 12.3 Liquid Biopsy Market: Share by Application (USD Billion, %)
Figure 12.4 Liquid Biopsy Market: Share by Indication (%)
Figure 12.5 Liquid Biopsy Market: Share by Type of Marker (%)
Figure 12.6 Liquid Biopsy Market: Share by Type of Sample (%)
Figure 12.7 Liquid Biopsy Market: Share by Geography (%)
Figure 12.8 Other Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
Figure 13.1 Non-Invasive Cancer Diagnostics Market (USD Billion), 2017, 2023 and 2030
LIST OF TABLES
Table 3.1 Survival on Early Diagnosis of Cancer
Table 3.2 Cost of Biopsy for Different Cancer Indications (in USD)
Table 3.3 Common Endoscopic Procedures
Table 4.1 Examples of Tumor Markers
Table 5.1 Liquid Biopsy Tests: Development Landscape
Table 5.2 Liquid Biopsy Tests: Distribution by Type of Application
Table 5.3 Liquid Biopsy Tests: Distribution by Geographical Coverage
Table 5.4 Liquid Biopsy: Technologies
Table 5.5 Liquid Biopsy: Systems and Instruments
Table 7.1 Liquid Biopsy: Tests Profiled
Table 7.2 Liquid Biopsy: Systems / Technologies Profiled
Table 7.3 Comparison of Clinical Sensitivity of BioFluidica Technology and CELLSEARCH® Technology
Table 7.4 Cancertrack: Biomarkers Detected
Table 7.5 SMSEQ™ Platform: Genes Detected
Table 7.6 CellMax Life: Publications
Table 7.7 CellMax Life: Posters / Presentations at Different Conferences
Table 7.8 CELLSEARCH® CTC Test: Cut-offs for Disease Prognosis
Table 7.9 CELLSEARCH® CTC Test: Publications
Table 7.10 cobas® EGFR Mutation Test v2: Publications
Table 7.11 LiquidBiopsy® Rare Cell Isolation: Specifications
Table 7.12 Cynvenio Biosystems: Publications
Table 7.13 Cynvenio Biosystems: Posters / Presentations at Different Conferences
Table 7.14 Metastat: Site Specific Biomarkers
Table 7.15 R.G.C.C. Group: Publications
Table 7.16 R.G.C.C. Group: Posters at Different Conferences
Table 7.17 R.G.C.C. Group: Presentations at Different Conferences
Table 7.18 BEAMing Technology: Publications
Table 7.19 BEAMing Technology: Posters / Presentations at Different Conferences
Table 7.20 PrediSeq: Gene Panel
Table 7.21 ViewRNA™ CTC Kits: Key Features
Table 7.22 Velox™: Potential Indications
Table 7.23 ApoStream® System: Specifications
Table 7.24 Comparison Between ApoStream® CTC Platform and CELLSEARCH® CTC Platform
Table 7.25 ApoCell: Posters / Presentations at Different Conferences
Table 7.26 Parsortix™ System: Publications
Table 7.27 Parsortix™ System: Posters / Presentations at Different Conferences
Table 8.1 Liquid Biopsy Market: Funding Instances, 2011-2017
Table 8.2 Liquid Biopsy Market: Types of Funding Instances, 2011-2017
Table 9.1 Company Valuation Analysis: Sample Dataset
Table 9.2 Company Valuation Analysis: Weighted Average Evaluation
Table 9.3 Company Valuation Analysis: Estimated Valuation
Table 10.1 Liquid Biopsy: List of Companies Profiled
Table 10.2 Biocartis: Portfolio of Liquid Biopsy Tests
Table 10.3 Idylla™ ctBRAF Mutation Assay: Features
Table 10.4 Idylla™ ctKRAS Mutation Assay: Features
Table 10.5 Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay: Features
Table 10.6 Biocept: Portfolio of Liquid Biopsy Tests
Table 10.7 Biodesix: Funding Instances
Table 10.8 Biodesix: Portfolio of Liquid Biopsy Tests
Table 10.9 VeriStrat® Test: Publications
Table 10.10 Exosome Diagnostics: Funding Instances
Table 10.11 Exosome Diagnostics: Portfolio of Liquid Biopsy Tests
Table 10.12 Oncotype SEQ™ Liquid Select Mutation Panel: Clinical Results
Table 10.13 Guardant Health: Funding Instances
Table 10.14 NeoGenomics Laboratories: Portfolio of Liquid Biopsy Tests
Table 10.15 NeoLAB™ HEME: Multiplex Profiles
Table 10.16 NeoGenomics Laboratories: Publications
Table 10.17 Personal Genome Diagnostics: Funding Instances
Table 10.18 Personal Genome Diagnostics: Portfolio of Liquid Biopsy Tests
Table 10.19 MetDETECT™: Specifications
Table 10.20 QIAGEN: Portfolio of Liquid Biopsy Tests
Table 10.21 Q1Aamp® Circulating Nucleic Acid Kit: Specifications
Table 10.22 ICEme Kits: Number of Possible COSMIC Mutations and Insertions / Deletions
Table 10.23 Transgenomic: Portfolio of Liquid Biopsy Tests
Table 10.24 MX-ICP CRC Analysis: Genes Analyzed and Recommended Treatment Options
Table 10.25 MX-ICP Melanoma Analysis: Genes Analyzed and Recommended Treatment Options
Table 10.26 MX-ICP NSCLC Analysis: Genes Analyzed and Recommended Treatment Options
Table 10.27 MX-ICP: Single-Gene Liquid Biopsy Tests
Table 10.28 Trovagene: Portfolio of Liquid Biopsy Tests
Table 10.29 Trovera™ Tests: Posters / Presentations at Different Conferences
Table 11.1 Other Non-Invasive Cancer Diagnostics: Market Landscape
Table 11.2 Survey Response: Overview of the Participating Companies
Table 11.3 Survey Response: Seniority Level of Respondents
Table 11.4 Survey Response: Type of Product Portfolio
Table 11.5 Survey Response: Type of Products / Services Offered
Table 11.6 Survey Response: Type of Application
Table 11.7 Survey Response: Availability of the Products
Table 11.8 Survey Response: Likely Liquid Biopsy Market Size (2030)
Table 11.9 Survey Response: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
Table 12.1 Liquid Biopsy for Early Diagnosis: Forecast Assumptions and Data Points
Table 12.2 Liquid Biopsy for Patient Monitoring: Forecast Assumptions and Data Points
Table 12.3 Liquid Biopsy for Recurrence Monitoring: Forecast Assumptions and Data Points
Table 12.4 Key Indications: Forecast Assumptions and Data Points
Table 15.1 Worldwide Incidence: Distribution by Type of Cancer
Table 15.2 Lung Cancer: Estimated New Cases in 2016 (In Thousands)
Table 15.3 Breast Cancer: Estimated New Cases in 2016 (In Thousands)
Table 15.4 Colorectal Cancer: Estimated New Cases in 2016 (In Thousands)
Table 15.5 Liquid Biopsy Tests: Distribution by Development Stage
Table 15.6 Liquid Biopsy Tests: Distribution by Sample Type
Table 15.7 Liquid Biopsy Tests: Distribution by Type of Markers Detected
Table 15.8 Liquid Biopsy Tests: Distribution by Indication
Table 15.9 Liquid Biopsy Tests: Distribution by Type of Application
Table 15.10 Liquid Biopsy Tests: Distribution by Leading Players
Table 15.11 Liquid Biopsy Market: Cumulative Funding Instances, 2011-2017
Table 15.12 Liquid Biopsy Market: Cumulative Funding Amount, 2011-2017 (USD Billion)
Table 15.13 Liquid Biopsy Tests: Distribution by Type of Funding Instances, 2011-2017
Table 15.14 Liquid Biopsy Tests: Distribution by Total Amount Invested, 2011-2017 (USD Billion)
Table 15.15 Leading Players: Distribution by Number of Funding Instances
Table 15.16 Company Valuation Analysis: Valuation Ratios, Input Dataset
Table 15.17 Biocartis: Annual Revenues, 2012-2016 (EUR Million)
Table 15.18 Biocept: Annual Revenues, 2012-2016 (USD Million)
Table 15.19 GeneStrat: Clinical Validation Data
Table 15.20 Genomic Health: Annual Revenues, 2010-2016 (USD Million)
Table 15.21 NeoGenomics Laboratory: Annual Revenues, 2010-2016 (USD Million)
Table 15.22 QIAGEN: Annual Revenues, 2010–2016 (USD Billion)
Table 15.23 QIAGEN Sales, 2016: Distribution by Business Segments
Table 15.24 Transgenomic: Annual Revenues, 2010 – Q1-Q3 2016 (USD Million)
Table 15.25 Trovagene: Annual Revenues, 2010–2016 (USD Million)
Table 15.26 Survey Analysis: Distribution by Geography
Table 15.27 Survey Analysis: Seniority Levels of Respondents
Table 15.28 Survey Analysis: Distribution by Type of Product Portfolio
Table 15.29 Survey Analysis: Distribution by Type of Products / Services Offered
Table 15.30 Survey Analysis: Distribution by Type of Application
Table 15.31 Survey Analysis: Distribution by Availability of Products
Table 15.32 Survey Analysis: Likely Liquid Biopsy Market Size (2030)
Table 15.33 Survey Analysis: Likely Other Non-Invasive Cancer Diagnostics Market Size (2030)
Table 15.34 Liquid Biopsy Market: Distribution of Patient Population into Risk Groups
Table 15.35 Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
Table 15.36 Non-Invasive Cancer Diagnostics Market (2017-2030): Optimistic Scenario (USD Billion)
Table 15.37 Non-Invasive Cancer Diagnostics Market (2017-2030): Conservative Scenario (USD Billion)
Table 15.38 Liquid Biopsy Market (2017-2030): Base Scenario (USD Billion)
Table 15.39 Liquid Biopsy Market (2017-2030): Optimistic Scenario (USD Billion)
Table 15.40 Liquid Biopsy Market (2017-2030): Conservative Scenario (USD Billion)
Table 15.41 Liquid Biopsy Market: Share by Application, (USD Billion, %)
Table 15.42 Liquid Biopsy Market: Share by Indication, (%)
Table 15.43 Liquid Biopsy Market: Share by Type of Marker, (%)
Table 15.44 Liquid Biopsy Market: Share by Type of Sample, (%)
Table 15.45 Liquid Biopsy Market: Share by Type of Marker, (%)
Table 15.46 Other Non-Invasive Cancer Diagnostics Market (2017-2030): Base Scenario (USD Billion)
Table 15.47 Other Non-Invasive Cancer Diagnostics Market (2017-2030): Optimistic Scenario (USD Billion)
Table 15.48 Other Non-Invasive Cancer Diagnostics Market (2017-2030): Conservative Scenario (USD Billion)
Table 15.49 Non-Invasive Cancer Diagnostics Market (USD Billion), 2017, 2023 and 2030

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report